Burning Rock Biotech (BNR) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Burning Rock Biotech (BNR) has outperformed Myriad Genetics (MYGN) over the past year, gaining 70.8% versus a loss of 45.0%. Over five years, MYGN leads with a -86.8% price change compared with -89.4% for BNR. Myriad Genetics is the larger company by market cap ($412.2 million vs $163.4 million), about 2.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNR | MYGN |
|---|---|---|
| Share price | $15.49 | $4.31 |
| Market cap | $163.36M | $412.25M |
| 1-day change | +3.27% | +2.62% |
| YTD return | -24.57% | -31.71% |
| 1-year return | +70.79% | -45.03% |
| 5-year return | -89.42% | -86.77% |
| EPS (TTM) | $-0.80 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $41.72 | $8.59 |
| 52-week low | $6.79 | $2.74 |
| Distance from 52-week high | -62.87% | -49.83% |
| Analyst consensus | — | hold |
| Avg. price target upside | — | -9.28% |
| Average volume | 28.59K | 2.04M |
| Shares outstanding | 8.81M | 95.65M |
| Employees | 667 | 2,700 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Myriad Genetics is about 2.5 times larger than Burning Rock Biotech by market value ($412.25M vs $163.36M).
- BNR has outperformed MYGN by 115.8 percentage points over the past year.
About Burning Rock Biotech
BNR stock →Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Health Care · Medical Specialities · 667 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
BNR vs MYGN FAQ
Which is bigger, Burning Rock Biotech or Myriad Genetics?
Myriad Genetics (MYGN) is larger, with a market capitalization of $412.25M compared with $163.36M for Burning Rock Biotech (BNR).
Which stock has performed better over the past year, BNR or MYGN?
BNR returned +70.79% over the past 12 months, compared with -45.03% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Burning Rock Biotech and Myriad Genetics in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Burning Rock Biotech and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Myriad Genetics.